Biotechnology

Friday Sep 15, 2023 - 9:55 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $1.33M Registered Direct

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. The company today announced its entry into a definitive agreement for the purchase and sale of 1,146,552 of the company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing 400 ordinary shares, at a…

Thursday Sep 14, 2023 - 1:47 pm

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Collaborates to Unlock the Value of Brands Through Strategic Acquisitions

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery, and manufacturing of psychotropic products, recently announced the acquisition of BlueSky Wellness Inc., along with its portfolio of brands, which adds psychotropic products to its catalog and expands its footprint into the global wellness market. BlueSky wellness-focused ecommerce brands include Keoni, Keoni Sport, Blush Wellness and AMMA Healing, which, in…

Wednesday Sep 13, 2023 - 10:12 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Announces Acquisition of BlueSky Wellness, Expands Footprint in Global Wellness Market

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery and manufacturing of psychotropic products, is acquiring BlueSky Wellness Inc. and the BlueSky portfolio of brands. According to the announcement, the acquisition adds psychotropic products to the company’s catalog, enabling LSDI to expand its footprint in the global wellness market. BlueSky Wellness brands include Keoni, Keoni Sport, Blush Wellness and…

Wednesday Sep 13, 2023 - 10:06 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Coverage Initiated by Singular Research

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that Singular Research has initiated analyst coverage on FSD Pharma. The company has not paid for the research report prepared by Singular Research, and all reports on FSD Pharma…

Tuesday Sep 12, 2023 - 10:00 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) to Acquire BlueSky Wellness Inc. in All-Stock Transaction

Lucy Scientific Discovery (NASDAQ: LSDI) is the leader in the psychotropic industry, which recently celebrated the acquisition of the intellectual property of High Times, the most iconic brand in the cannabis industry. Today the company announced an agreement to acquire BlueSky Wellness Inc. and its portfolio of brands, expanding Lucy’s footprint into the growing global wellness category by adding psychotropic products to its capabilities. BlueSky…

Monday Sep 11, 2023 - 2:03 pm

InvestorNewsBreaks – SOHM Inc. (SHMN) Names Seasoned Veteran as VP of Quality

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, has appointment a new vice president of quality. The company announced that Wm. Dewey Rushing will be serving as SOHM vice president for quality. Rushing has been serving on the company’s advisory board member and that experience combined with his impressive background in management and leadership…

Monday Sep 11, 2023 - 11:00 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation in H.C. Wainwright, LSX USA Congress 2023 and Upcoming Conferences

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., today announced that its CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York today and tomorrow (Sept. 11 and 12) and the LSX USA Congress 2023 in Boston this Wednesday and Thursday (Sept. 13 and 14). Investors…

Monday Sep 11, 2023 - 10:26 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) CEO Releases Stockholder Letter

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has issued a letter to its stockholders. The letter, from CEO Wa’el Hashad, contains a business update regarding the company’s development of its lead investigational product, Lomecel-B(TM), as well as steps taken to strengthen the board…

Friday Sep 08, 2023 - 12:23 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) ‘Strategically Important’ Patent Grants Protection in One of World’s Leading Oral Nicotine Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine.” The patent covers various forms and sources of nicotine, including nicotine benzoate, nicotine polacrilex, nicotine citrate, nicotine detartrate, and many others, for use in sublingual delivery formats like oral pouches. “The new U.S. patent is remarkable…

Friday Sep 08, 2023 - 11:58 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthening Position in Projected $51B Global Cannabis Market

Lucy Scientific Discovery (NASDAQ: LSDI) is featured in a recent FinancialNewsMedia (“FNM”) Editorial. The editorial provides an overview of LSDI’s position in a global cannabis market projected to hit $51 billion this year. According to the press release, the global cannabis market has seen consistent growth year after year, with increasing legalization of cannabis fueling that growth. The release notes that a recent Statista report…

Thursday Sep 07, 2023 - 1:29 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced enrollment of 200 of the expected 243 patients in the company’s ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent Glioblastoma Multiforme (“GBM”), an aggressive and incurable form of brain cancer. “As we have noted…

Thursday Sep 07, 2023 - 1:22 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright 25th Annual Global Investment Conference

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing, and commercialization of rare cannabinoids and cannabinoid analogs, today announced its participation in the H.C. Wainwright Global Investment Conference, which is taking place Sept. 11-13, 2023, in New York City. The on-demand presentation by InMed’s CEO Eric A. Adams will be available beginning at 7 a.m. ET on Sept. 11 via webcast, and…

Thursday Sep 07, 2023 - 12:02 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its CFO Ryan Confer will be providing an overview of the company's pioneering gene therapies for cancer and diabetes at the upcoming H.C. Wainwright 25th Annual Global Investment Conference. Confer’s presentation is scheduled to begin at 3:00 p.m. ET on Wednesday, Sep. 13,…

Thursday Sep 07, 2023 - 11:40 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces ELPIS 1 Trial Data Accepted for AHA Presentation, IBN Partnership

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be participating at the American Heart Association Scientific Sessions. The company announced that an abstract outlining long-term survival data from its ELPIS 1 trial of Lomecel-B(TM) for patients with HLHS has been accepted for presentation as a…

Thursday Sep 07, 2023 - 11:04 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Acquires High Times Intellectual Property, Featured in Financial News Media Article

Lucy Scientific Discovery (NASDAQ: LSDI) today announced the acquisition of the intellectual property (“IP”) of High Times, an iconic brand in the cannabis industry. In addition to the Hightimes.com domain, the transaction also includes the trademarks for the Cannabis Cup and 420.com brands and their respective domain names. In exchange, High Times will receive a 19.9% stake in Lucy's outstanding stock as well as performance-based…

Wednesday Sep 06, 2023 - 3:03 pm

InvestorNewsBreaks – Why RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, available by prescription for the treatment of acquired blepharoptosis (low-lying eyelid(s)) in adults. “UPNEEQ(R) (‘RVL-1201’) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (‘FDA’) for acquired blepharoptosis. The company received FDA approval in July 2020 and launched UPNEEQ(R) in…

Wednesday Sep 06, 2023 - 12:34 pm

InvestorNewsBreaks – HippoFi Inc. (ORHB) Collaborates to Bring ‘Innovative Technology to the Forefront of Spinal Treatments’

HippoFi (OTC: ORHB), a leading health care technology company and authority in spinal biologics, has announced a partnership with global medical technology leader Zimmer Biomet, aiming to redefine the spinal biologics landscape. According to the announcement, the collaboration will harness the combined expertise of both companies to introduce a novel synthetic biomaterial for bone growth, set for a 2024 launch under HippoFi’s subsidiary, PUR Biologics.…

Wednesday Sep 06, 2023 - 10:33 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.

BiondVax (NASDAQ: BVXV), a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new…

Tuesday Sep 05, 2023 - 10:44 am

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference

Longeveron (NASDAQ: LGVN, LGVNR), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty, today announced that its management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference. The event is slated to take place in New York City from Sept. 11-13, 2023. Longeveron’s CEO Wa’el…

Tuesday Sep 05, 2023 - 10:33 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, in New York City. According to the announcement, CNS Pharmaceuticals CEO Climaco is scheduled to present during the two-day…

Friday Sep 01, 2023 - 2:35 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently received coverage in analysis by Aegis Capital Corp. The report, which reiterated a buy recommendation and $70 target price for BVXV, contained analysis highlighting a deal valued at approximately $2.4 billion for…

Friday Sep 01, 2023 - 12:24 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China National Intellectual Property Administration. “The granted patent broadly covers the use of the company’s drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers. The REQORSA gene therapy in combination with Keytruda is…

Wednesday Aug 30, 2023 - 10:55 am

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released a statement congratulating GEDiCube on its joint effort to accelerate early diagnosis of cancer in clinical trials. GEDiCube is partnering with NVIDIA Inception on clinical trials focused on advancing a unique platform for early cancer detection. The platform combines techniques for boosting…

Friday Aug 25, 2023 - 2:01 pm

InvestorNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (“IL-17”) for the treatment of psoriasis, HS and other important indications. “BiondVax is now fast on the trail of developing what could be a very…

Thursday Aug 24, 2023 - 12:42 pm

InvestorNewsBreaks – SOHM, Inc. (SHMN) Announces Strategic Board Appointment of Dr. Krishna Bhat, MD, Ph.D., FACC

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced the appointment of Dr. Krishna Bhat, MD, Ph.D., FACC, an experienced bioscientist and cardiologist, to serve on its advisory board as a chief medical advisor. According to the update, Dr. Bhat has a practice of over 35 years in the field of clinical and…

Thursday Aug 24, 2023 - 10:00 am

InvestorNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, will be represented at the 25th annual H.C. Wainwright Global Investment Conference. The company announced that CEO Brian Markson will be participating in a fireside chat during the event, which is scheduled for Sept.…

Wednesday Aug 23, 2023 - 1:45 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Launching IND Program on DehydraTECH-CBD for Hypertension

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been published in eight peer-reviewed articles across six different publications. “The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is ‘Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study.’…

Wednesday Aug 23, 2023 - 1:16 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Clear Path to IND Submission for Innovative Cancer Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application (“IND”) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the U.S. Food and Drug Administration (“FDA”) on the company’s Pre-IND submission. The company’s proprietary, novel technology uses cell- and gene-therapy to promote renewed immune response against solid tumors. “We are…

Tuesday Aug 22, 2023 - 11:48 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Regulatory Expert as It Drives Important Clinical Programs Forward

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its appointment of Suzanne Thornton-Jones, Ph.D. as senior vice president, regulatory affairs. Dr. Thornton-Jones will leverage her expertise to guide Genprex’s regulatory submissions and strategy for its pipeline of gene therapy drug candidates. “We are delighted to welcome Dr. Thornton-Jones to the Genprex team…

Monday Aug 21, 2023 - 3:21 pm

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Results of Annual Meeting

IGC Pharma (NYSE American: IGC) has announced that during its annual meeting of stockholders scheduled for and convened on Aug. 18, 2023, (the “annual meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 26, 2023, were passed by the requisite vote of the stockholders. Only stockholders of record as of the record date of June…

Monday Aug 21, 2023 - 12:27 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDi Cube on Appointment of Expert in Clinical Medicine and Digital Health

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, on Aug. 9 announced an exclusive, binding letter of intent with GEDi Cube. Today Renovaro BioSciences congratulated GEDi Cube on its appointment of Dr. Lester Russell as its chief medical officer. “We are excited about the appointment of Dr. Russell,” said Dr. Mark Dybul, CEO of Renovaro BioSciences. “As a seasoned…

Friday Aug 18, 2023 - 11:09 am

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Discusses Substantial Scientific, Product Development Advances in Letter to Shareholders

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), earlier this year issued a letter to shareholders from its CEO Mark Dybul, MD, in which Dr. Dybul discussed scientific and product development advances and plans for the future. The advances included independently conducted studies that showed remarkably promising results, demonstrating and confirming proof-of-concept for the company’s cell-gene-immunotherapy for pancreatic cancer and, potentially, other solid tumors, as well…

Thursday Aug 17, 2023 - 1:28 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Presentation of ‘Impressive’ Results from Proof-of-Concept Studies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in March of 2023 announced that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer, presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (“UCLA”). According to the announcement, the experiments demonstrated highly significant reductions in the weight and volume…

Thursday Aug 17, 2023 - 12:23 pm

InvestorNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Spotlighted in New Cantor Fitzgerald Research Brief

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, is featured in a recent Cantor Fitzgerald research brief. Noting that the stock “looks even more interesting post solid quarter and ahead of potential strategic acquisition,” the research brief reiterated its previous Overweight (“OW”)…

Wednesday Aug 16, 2023 - 12:49 pm

InvestorNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Enters into Agreements for $5M Registered Direct Offering

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has entered into definitive agreements. The offering is expected to close on or about Aug. 18, 2023, and will be subject to customary closing conditions. The company anticipates gross proceeds from the registered direct offering…

Wednesday Aug 16, 2023 - 11:43 am

InvestorNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Subsidiary Announces Pricing of Its IPO

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced that SRM Entertainment Inc. (NASDAQ: SRM), currently a subsidiary of the company, announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a price to the public of $5.00 per share. Gross proceeds from the offering are expected to be $6.25 million. The shares of…

Wednesday Aug 16, 2023 - 11:36 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis titled the report “Good Things Coming” and gave BVXV a Buy rating. The research report noted that BiondVax has signed an exclusive worldwide license agreement to develop and commercialize…

Wednesday Aug 16, 2023 - 11:06 am

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent for its oncology platform, as well as promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. Scientists at the Fred Hutchinson Cancer Center were also, at that time, conducting…

Tuesday Aug 15, 2023 - 1:20 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Committed to Rapid Advancement of Its Proprietary Oncology Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in late 2022, was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world’s deadliest solid tumors. “We are incredibly excited to have been awarded this patent for Enochian’s allogeneic cell and gene therapy cancer treatment platform, especially following promising early study results,” said…

Monday Aug 14, 2023 - 2:33 pm

InvestorNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Announces Q2 2023 Results, Strategic Business Review Update

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company today announced financial results for the three months ended June 30, 2023, and provided an update on its business review. “During the past several months, we have focused on expense reduction to…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions